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1. Introduction 
Discovery of new bioactive leads for subsequent optimization into drugs is both time 
consuming and expensive process. Two main approaches are currently available for lead 
discovery, namely, high throughput (in vitro) screening and computer-aided virtual (in 
silico) screening. Normally, in silico techniques are implemented as pre-filters to enrich the 
success rates of high throughput screening campaigns. 
Computer-aided lead discovery techniques can be divided into two main methodologies: (1) 
Structure-based and (2) ligand-based methods. Structure-based methods depend on the 
availability of three-dimensional (3D) structure for the targeted biomolecule (enzyme of 
receptor). The target structure is normally employed as template to design sterically and 
electronically complementary ligands. On the other hand, ligand-based methods rely on 
assessing physicochemical and structural similarities among potent ligands and try to 
discern ligands' structural features responsible for high affinities from those responsible for 
poor affinities. In other words, ligand-based methods rely completely on ligand factors to 
assess ligand-receptor affinities. 
Structure-based drug design can be divided into two major methodologies: de novo and 
docking-based design. De novo design involves the use of algorithms that construct virtual 
ligands inside binding pockets.1-3 On the other hand, docking involves fitting virtual 
ligands, usually from large virtual libraries, into targeted binding sites employing computer 
algorithms that rely on force fields to calculate attractive and repulsive interactions within 
virtual ligand-protein complexes.1-4 
The 3D structures of targeted receptors or enzymes are generally obtained via X-ray 
crystallographic scattering, nuclear magnetic resonance (NMR) or homology modeling.1-4 
However, reliance on crystallographic structures represents a major problem for structure-
based design. Crystallographic structures are limited by inadequate resolution5 and 
crystallization-related artifacts of the ligand-protein complex.6-8 Moreover, crystallographic 
structures generally ignore structural heterogeneity related to protein anisotropic motion 
and discrete conformational substrates.9 
Moreover, molecular docking, which is basically a conformational sampling procedure in 
which various docked conformations are explored to identify the right one, can be very 
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challenging problem given the degree of conformational flexibility at the ligand-
macromolecular level.10-12 Although docking programs employ diverse methodologies to 
evaluate different ligand conformations within binding pockets,13-23 conformational 
sampling must be guided by scoring function(s) to evaluate the fitness between the protein 
and the ligand.4,24-29 The final docked conformations are selected according to their scores. 
Unfortunately, the sheer complexity of the underlying ligand-receptor molecular 
interactions extremely complicate free energy calculations and undermine the ability of 
scoring functions to evaluate binding free energies correctly in order to rank different 
potential ligand–receptor complexes.1,3,5-8,10,30,31,39 
 In addition to deciding the optimal docking/scoring combination for a particular docking 
problem, the molecular modeler must decide whether to leave crystallographically explicit 
water molecules in the binding site or not prior to ligand docking.32-37 Furthermore, the fact 
that crystallographic structures lack information on hydrogen atoms means that it should be 
appropriately assumed whether ionizable moieties embedded within the binding site exist 
in their ionized form or not.36,38  
Additional to the previous problems, use of single protein conformation for designing new 
ligands ignores important dynamic aspects of protein-ligand binding. In particular, the 
“induced fit'' effects are ignored.40,41 Unfortunately, all current computational models 
directed towards assessing the flexibility of macromolecular binding sites (e.g., soft 
receptors42,43; few critical rotable degrees of freedom in the receptor binding site43-48; 
systematic conformer searches of amino acids’ side chains at the binding site49; molecular 
dynamics and free energy calculations conducted on flexible enzyme50,51; use of multiple 
crystallographic receptor structures43,52) suffer from two major drawbacks. Firstly, their 
computational cost, which reduces their effectiveness in virtual screening and fast docking, 
and secondly, their complete reliance on crystallographic structures.  
The drawbacks of structure-based methods prompted us to introduce an interesting and 
novel ligand-based approach as a tool for characterizing binding sites' flexibilities. This 
approach ignores the protein template and focuses completely on the ligand side. It is 
carried out over two subsequent stages. Firstly, the pharmacophoric space of the targeted 
enzyme is extensively explored utilizing the three-dimensional Quantitative Structure 
Activity Relationship (3D-QSAR) software program CATALYST. The resulting binding 
models (hundreds) are then in allowed to compete within the context of classical 
quantitative structure-activity relationship analyses (QSAR) employing genetic algorithm 
(GA) and multiple linear regression (MLR) analyses. This process selects optimal 
combination of orthogonal pharmacophores that best explain the observed bioactivities, i.e., 
best possible QSAR model. Such combination of binding pharmacophores should 
correspond to accessible binding modes available for ligands within a particular binding 
pocket. 
We previously reported the successful use of this combination to probe the induced fit 
flexibilities of activated factor X53 and towards the discovery of new inhibitory leads against 
glycogen synthase kinase-3β,54 bacterial MurF,55 protein tyrosine phosphatase,56 DPP IV,57 
hormone sensitive lipase,58 β-secretase,59 influenza neuraminidase,60 cholesteryl ester 
transfer protein,61 cycline dependent kinase,62 Heat shock protein,63 estrogen receptor β,64 β-
D-Glucosidase,65 and β-D-Galactosidase.66 
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The author intends in this chapter to discuss the basic theoretical principles of this 
successful ligand-based approach and to provide interested audiences with experimental 
details related to this approach.  
The modeling process of this approach can be divided in the following steps: 
2. Data mining and conformational coverage  
Firstly, the literature is extensively surveyed to identify as many reported structurally 
diverse ligands against the selected target as possible. The collected compounds must satisfy 
two important prerequisites: (i) they should be all bioassayed by a single procedure. 
Consistency in bioassay is a major requirement for QSAR modeling as it is not possible to 
model bioactivity data generated via more than one bioassay procedure. (ii) They must 
exhibit wide bioactivity range, i.e., over > 4 logarthmic cycles.  
Initially, the 2D structures of the inhibitors are imported into the modeling package 
(CATALYST) and converted automatically into plausible 3D single conformer 
representations and energy minimized to the closest local minimum. The resulting single 
conformer 3D structures are normally used as starting points for conformational analysis for 
pharmacophore modeling and in the determination of various molecular descriptors for 
QSAR modeling. 
The conformational space of each ligand is extensively sampled usually utilizing the poling 
algorithm employed within the CONFIRM module of CATALYST.67 Efficient 
conformational coverage guarantees minimum conformation-related noise during 
pharmacophore generation and validation stages because pharmacophore generation and 
pharmacophore-based search procedures are known for their sensitivity to inadequate 
conformational sampling within the training compounds.60  
The logarithm of measured IC50, EC50 or Ki values are used in pharmacophore modeling and 
QSAR analysis, thus correlating the data linear to the free energy change. 
2.1 Exploration of pharmacophoric space  
2.1.1 The algorithm 
Normally we implement the HYPOGEN module within CATALYST package to explore the 
pharmacophoric space of different ligands. CATALYST-HYPOGEN enables automatic 
pharmacophore construction by using a collection of at least 16 molecules with bioactivities 
spanning over 3.5 orders of magnitude.67 
CATALYST-HYPOGEN models drug-receptor interaction using information derived from 
the ligand structure. It identifies a 3D array of a maximum of five chemical features common 
to active training molecules, which provides a relative alignment for each input molecule 
consistent with their binding to a proposed common receptor site. The chemical features 
considered can be hydrogen bond donors and acceptors (HBDs and HBAs), aliphatic and 
aromatic hydrophobes (Hbic), positive and negative ionizable (PosIon and NegIon) groups 
and aromatic planes (RingArom). CATALYST pharmacophores have been used as 3D 
queries for database searching and in 3D-QSAR studies.54-66 
www.intechopen.com
 
Virtual Screening 
 
6 
Although pharmacophore modeling employing HYPOGEN has been heavily reviewed in 
the literature,68-76 a brief discussion of this algorithm is provided herein to allow better 
readability of the chapter.  
HYPOGEN pharmacophore exploration proceeds through three successive phases: the 
constructive phase, subtractive phase and optimization phase.67-76 
During the constructive phase, CATALYST generates common conformational alignments 
among the most-active training compounds. Only molecular alignments based on a 
maximum of five chemical features are considered. The program identifies a particular 
compound as being within the most active category if it satisfies equation (1).73 
  (MAct x UncMAct)  (Act / UncAct) > 0.0  (1) 
Where “MAct” is the activity of the most active compound in the training set, “Unc” is the 
uncertainty of the compounds and “Act” is the activity of the training compounds under 
question. However, if there are more than eight most-active inhibitors, only the top eight are 
used.  
In the subsequent subtractive phase, CATALYST eliminates some hypotheses that fit 
inactive training compounds. A particular training compound is defined as being inactive if 
it satisfies equation (2): 67-76 
  Log (Act) – log (MAct) > 3.5  (2)  
However, in the optimization phase, CATALYST applies fine perturbations in the form of 
vectored feature rotation, adding new feature and/or removing a feature, to selected 
hypotheses that survived the subtractive phase, in an attempt to find new models of 
enhanced bioactivity/mapping correlation, i.e., improved 3D-QSAR properties.67-76  
Eventually, CATALYST selects the highest-ranking models (10 by default) and presents 
them as the optimal pharmacophore hypotheses resulting from the particular automatic 
modeling run. 
2.1.2 Selection of training subsets 
The fact that pharmacophore modeling requires limited number of carefully selected 
training compounds (from 16-45 compounds only)67-76 that exhibit bioactivity variations 
attributable solely to the presence or absence of pharmacophoric features, i.e., not due to 
steric or electronic factors, makes it impossible to explore the pharmacophore space of large 
training sets in one shot (e.g., we normally collect more that 100 compounds), partly because 
CATALYST-HYPOGEN is not suited to handle large number of compounds and partly 
because pharmacophore modeling is generally confused by electronic and steric bioactivity 
modifying factors commonly encountered in SAR data. This dilemma prompted us to break 
compound lists into smaller training subsets compatible with pharmacophore modeling, i.e., 
of bioactivity variations attributable solely to the presence or absence of pharmacophoric 
features. Nevertheless, the basic problem in this approach is to identify a particular 
training set capable of representing the whole list of collected compounds. This problem 
can be very significant in cases of large SAR lists. We found that the best way to solve this 
problem is by exploring the pharmacophoric space of several carefully selected training 
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subsets, i.e., from the whole list of collected compounds, followed by allowing the 
resulting pharmacophores to compete within the context of genetic function 
approximation-based quantitative structure-activity relationship (GFA-QSAR) analysis 
such that the best pharmacophore(s) capable of explaining bioactivity variations across 
the whole list of collected compounds is(are) selected. However, since pharmacophore 
models fail in explaining electronic and steric bioactivity-modulating effects, the GFA-
QSAR process should be allowed to select other 2D physicochemical descriptors to 
complement the selected pharmacophore(s) (see below).  
The training compounds in these subsets are selected in such away to guarantee maximal 
3D diversity and continuous bioactivity spread over more than 3.5 logarithmic cycles. 
Moreover, training subsets are selected in such a way that their member compounds share 
certain apparent 3D SAR rules (by visual evaluation).  
We usually give special emphasis to the 3D diversity of the most active compounds in each 
training subset because of their significant influence on the extent of the evaluated 
pharmacophoric space during the constructive phase of HYPOGEN algorithm. However, it 
must be mentioned that not all collected compounds are incorporated in the pharmacophore 
training subsets, in fact, compounds that exhibit limited diversity or significant bioactivity-
modifying steric or electronic influences are excluded from the training subsets. 
2.1.3 Modeling boundaries  
HYPOGEN implements an optimization algorithm that evaluates large number of potential 
binding models for a particular target through fine perturbations to hypotheses that 
survived the constructive and subtractive phases of the modeling algorithm.67-76 The extent 
of the evaluated pharmacophoric space is reflected by the configuration (Config.) cost 
calculated for each modeling run. It is generally recommended that the Config. cost of any 
HYPOGEN run not to exceed 17 (corresponding to 217 hypotheses to be assessed by 
HYPOGEN) to guarantee thorough analysis of all models.71-73 The size of the investigated 
pharmacophoric space is a function of training compounds, selected input chemical features 
and other CATALYST control parameters.67-76 
We envisaged that restricting the size of explored pharmacophoric space should improve 
the efficiency of optimization via allowing efficient assessment of limited number of 
pharmacophoric models. On the other hand, extreme restrictions imposed on the evaluated 
pharmacophoric space might reduce the possibility of discovering optimal binding 
hypotheses, as they might occur outside the “boundaries” of the evaluated space. 
Therefore, we normally explore the pharmacophoric space of targeted ligands under 
reasonably imposed "boundaries" through numerous HYPOGEN runs and employing 
several carefully selected training subsets. 
Guided by our rationally restricted pharmacophoric exploration concept, we usually restrict 
HYPOGEN to explore pharmacophoric models incorporating limited number of features, 
e.g., from zero to one negative NegIon, or PosIon features or from zero to three HBA, Hbic, 
and RingArom features instead of the default range of zero to five. Furthermore, we 
normally instructed HYPOGEN to explore only 4- and 5-featured pharmacophores, i.e., 
ignore models of lesser number of features in order to further narrow the investigated 
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pharmacophoric space and to better represent the diverse interactions between known 
ligands and binding pockets. In fact, three- and two-featured pharmacophores are rather 
promiscuous as 3D search queries and not adequate descriptions of ligand-receptor binding. 
2.1.4 Assessment of generated pharmacophore models 
When generating hypotheses, CATALYST attempts to minimize a cost function consisting of 
three terms: Weight cost, Error cost and Configuration cost.67-76 Weight cost is a value that 
increases as the feature weight in a model deviates from an ideal value of 2. The deviation 
between the estimated activities of the training set and their experimentally determined 
values adds to the error cost. The activity of any compound can be estimated from a 
particular hypothesis through equation (3).73 
 Log (Estimated Activity) = I + Fit  (3) 
Where, I = the intercept of the regression line obtained by plotting the log of the biological 
activity of the training set compounds against the Fit values of the training compounds. The 
Fit value for any compound is obtained automatically employing equation (4).73  
 Fit = Σ mapped hypothesis features × W [1−Σ (disp/tol) 2]  (4) 
Where, Σ mapped hypothesis features represents the number of pharmacophore features 
that successfully superimpose (i.e., map or overlap with) corresponding chemical moieties 
within the fitted compound, W is the weight of the corresponding hypothesis feature 
spheres. This value is fixed to 1.0 in CATALYST-generated models. disp is the distance 
between the center of a particular pharmacophoric sphere (feature centroid) and the center 
of the corresponding superimposed chemical moiety of the fitted compound; tol is the 
radius of the pharmacophoric feature sphere (known as Tolerance, equals to 1.6 Å by 
default). Σ (disp/tol)2 is the summation of (disp/tol)2 values for all pharmacophoric features 
that successfully superimpose corresponding chemical functionalities in the fitted 
compound.67-76  
The third cost term, i.e., the configuration cost, penalizes the complexity of the hypothesis. 
This is a fixed cost, which is equal to the entropy of the hypothesis space. The more the 
numbers of features (a maximum of five) in a generated hypothesis, the higher is the 
entropy with subsequent increase in this cost. The overall cost (total cost) of a hypothesis is 
calculated by summing over the three cost factors. However, error cost is the main 
contributor to the total cost.  
CATALYST also calculates the cost of the null hypothesis, which presumes that there is no 
relationship in the data and that experimental activities are normally distributed about their 
mean. Accordingly, the greater the difference from the null hypothesis cost, the more likely 
that the hypothesis does not reflect a chance correlation. In a successful automatic modeling 
run, CATALYST ranks the generated models according to their total costs.67-76 
An additional approach to assess the quality of CATALYST-HYPOGEN pharmacophores is 
to cross-validate them using the Cat-Scramble module implemented in CATALYST. This 
validation procedure is based on Fisher’s randomization test.43 In this validation test, a 95% 
confidence level was selected, which instruct CATALYST to generate 19 random 
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spreadsheets by the Cat-Scramble command. Subsequently, CATALYST-HYPOGEN is 
challenged to use these random spreadsheets to generate hypotheses using exactly the same 
features and parameters used in generating the initial unscrambled hypotheses.67 Success in 
generating pharmacophores of comparable cost criteria to those produced by the original 
unscrambled data reduces the confidence in the training compounds and the unscrambled 
original pharmacophore models.  
Eventually, the top 10 binding hypotheses (i.e., pharmacophores) from each automatic 
HYPOGEN run are automatically ranked according to their corresponding "total cost" 
values and presented as output of the HYPOGEN run. 
2.2 Clustering of successful pharmacophore hypotheses 
Because the number of generated pharmacophores during our pharmacophore exploration 
step is usually large (> 60 model) and they usually share several 3D features and properties 
(cost criteria, Cat.scramble confidence, etc …), we normally cluster the resulting models into 
limited number of groups (10-30) utilizing the hierarchical average linkage method available 
in CATALYST. The highest-ranking hypothesis within each cluster (i.e., of lowest cost or 
highest correlation with bioactivity of the whole collected list) is selected to represent the 
corresponding cluster in subsequent QSAR modeling.  
Clustering aims at avoiding overloading genetic function approximation-multiple linear 
regression (GFA-MLR), implemented during QSAR modeling, with numerous independent 
variables, which may allow the emergence of less-than-optimal regression models.  
2.3 QSAR modeling 
Pharmacophoric hypotheses are important tools in drug design and discovery as they 
provide excellent insights into ligand-macromolecule recognition and they can be used to 
mine for new biologically interesting scaffolds. However, their predictive value as 3D-QSAR 
models is usually limited by steric shielding and bioactivity-enhancing or -reducing 
auxiliary groups.76 This point combined with the fact that pharmacophore exploration 
usually furnish several binding hypotheses of comparable success criteria and 3D features 
prompt us to use classical QSAR analysis to search for optimal combination of 
pharmacophore(s) and other 2D descriptors capable of explaining bioactivity variation 
across the whole list of collected inhibitors. We normally employ genetic function 
approximation and multiple linear regression QSAR (GFA-MLR-QSAR) analysis to search 
for an optimal QSAR equation(s) using the logarithm of measured 1/IC50 or 1/Ki values are 
as dependent variables (thus correlating the data linear to the free energy change).  
GFA-MLR-QSAR selects optimal descriptor combinations based on the Darwinian concept 
of genetic evolution whereby the statistical criteria of regression models from different 
descriptor combinations (chromosomes) are employed as fitness criteria.77 GFA-MLR-QSAR 
analysis is employed to explore various combinations of pharmacophores and other 
structural descriptors and to evaluate their statistical properties as predictive QSAR models.  
Representative pharmacophore hypotheses (selected during the clustering stage) are fitted 
against all collected ligands and their fit values (determined by equation 4) are enrolled, 
together with other 2D and 1D structural descriptors, as independent variables (genes) in a 
cycle of GFA-MLR-QSAR analysis over thousands of iterations.77 
www.intechopen.com
 
Virtual Screening 
 
10
Other structural descriptors include various simple and valence connectivity indices, 
electro-topological state indices and other molecular descriptors (e.g., logarithm of partition 
coefficient, polarizability, dipole moment, molecular volume, molecular weight, molecular 
surface area, etc.).77 
However, to assess the predictive power of the optimal QSAR models on external set of 
inhibitors, we usually randomly select around 20% of the collected ligands and employ 
them as external testing molecules for validating optimal QSAR model(s) (r2PRESS). 
Moreover, all QSAR models are cross-validated automatically using the leave-one-out cross-
validation.77  
Emergence of two or more orthogonal pharmacophoric models in the optimal QSAR model 
suggests the existence of complementary two or more corresponding binding modes 
accessible to ligands within the binding pocket of target protein, i.e., one of the 
pharmacophores can optimally explain the bioactivities of some training inhibitors, while 
the others explain the remaining inhibitors. Such conclusions were reached about the 
binding pockets of several targets, e.g., factor Xa, GSK-3and Mur F.57-63  
2.4 Final validation of optimal QSAR model and associated pharmacophores 
To establish the validity of optimal GFA-selected QSAR model and associated 
pharmacophore(s), we normally implement two validation methods: (1) Receiver-Operating 
Characteristic (ROC) curve analysis, and (2) Comparing QSAR-selected pharmacophore(s) 
with the corresponding binding site, however, this is only done upon having available 
crystallographic structure of the targeted receptor.  
2.4.1 Receiver Operating Characteristic (ROC) curve analysis 
In ROC analysis, the ability of a particular pharmacophore model to correctly classify a list 
of compounds as actives or inactives is indicated by the area under the curve (AUC) of the 
corresponding ROC as well as other parameters, namely, overall accuracy, overall 
specificity, overall true positive rate and overall false negative rate.78-79  
The testing list for ROC analyses are usually prepared as described by Verdonk and co-
workers.78 Briefly, decoy compounds are selected based on three basic one-dimensional 
(1D) properties that allow the assessment of distance (D) between two molecules (e.g., i 
and j): (1) the number of hydrogen-bond donors (NumHBD); (2) number of hydrogen-
bond acceptors (NumHBA) and (3) count of nonpolar atoms (NP, defined as the 
summation of Cl, F, Br, I, S and C atoms in a particular molecule). For each active 
compound in the test set, the distance to the nearest other active compound is assessed by 
their Euclidean Distance (Equation 5):  
 2 2 2( , ) ( ) ( ) ( )i j i j i jD i j NumHBD NumHBD NumHBA NumHBA NP NP       (5) 
The minimum distances are then averaged over all active compounds (Dmin). Subsequently, 
for each active compound in the test set, around 40 decoys are randomly chosen from the 
ZINC database.80 The decoys are selected in such a way that they did not exceed Dmin 
distance from their corresponding active compound.  
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To diversify active members in the list, we exclude any active compound having zero 
distance ( ( , )D i j ) from other active compound(s) in the test set.  
The test set is then screened by each particular pharmacophore employing the "Best flexible 
search" option implemented in CATALYST, while the conformational spaces of the 
compounds are usually generated employing the "Fast conformation generation option" 
implemented in CATALYST. Compounds missing one or more features were discarded 
from the hit list. In-silico hits were scored employing their fit values as calculated by 
equation (4). 
The ROC curve analysis describes the sensitivity (Se or true positive rate, equation 6) for any 
possible change in the number of selected compounds (n) as a function of (1-Sp). Sp is 
defined as specificity or true negative rate (equation 7).79,81 
 
Number of Selected Actives TP
Se
Total Number of Actives TP FN
    (6) 
 
Number of Discarded Inactives TN
Sp
Total Number of Inactives TN FP
    (7) 
where, TP is the number of active compounds captured by the virtual screening method 
(true positives), FN is the number of active compounds discarded by the virtual screening 
method, TN is the number of discarded decoys (presumably inactives), while FP is the 
number of captured decoys (presumably inactive).79,81 
If all molecules scored by a virtual screening (VS) protocol with sufficient discriminatory 
power are ranked according to their score (i.e., fit values), starting with the best-scored 
molecule and ending with the molecule that got the lowest score, most of the actives will 
have a higher score than the decoys. Since some of the actives will be scored lower than 
decoys, an overlap between the distribution of active molecules and decoys will occur, 
which will lead to the prediction of false positives and false negatives.79,81 The selection of 
one score value as a threshold strongly influences the ratio of actives to decoys and therefore 
the validation of a VS method. The ROC curve method avoids the selection of a threshold by 
considering all Se and Sp pairs for each score threshold.79,81 A ROC curve is plotted by 
setting the score of the active molecule as the first threshold. Afterwards, the number of 
decoys within this cutoff is counted and the corresponding Se and Sp pair is calculated. This 
calculation is repeated for the active molecule with the second highest score and so forth, 
until the scores of all actives are considered as selection thresholds. 
The ROC curve representing ideal distributions, where no overlap between the scores of 
active molecules and decoys exists, proceeds from the origin to the upper-left corner until all 
the actives are retrieved and Se reaches the value of 1. In contrast to that, the ROC curve for 
a set of actives and decoys with randomly distributed scores tends towards the Se = 1-Sp 
line asymptotically with increasing number of actives and decoys.79,81 The success of a 
particular virtual screening workflow can be judged from the following criteria: 
1. Area under the ROC curve (AUC).79,81 In an optimal ROC curve an AUC value of 1 is 
obtained; however, random distributions cause an AUC value of 0.5. Virtual screening 
that performs better than a random discrimination of actives and decoys retrieve an 
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AUC value between 0.5 and 1, whereas an AUC value lower than 0.5 represents the 
unfavorable case of a virtual screening method that has a higher probability to assign 
the best scores to decoys than to actives.79,81 
2. Overall Accuracy (ACC): describes the percentage of correctly classified molecules by 
the screening protocol (equation 8). Testing compounds are assigned a binary score 
value of zero (compound not captured) or one (compound captured).79,81 
 . 1 .
TP TN A A
ACC Se Sp
N N N
         (8) 
where, N is the total number of compounds in the testing database, A is the number of true 
actives in the testing database. 
3. Overall specificity (SPC): describes the percentage of discarded inactives by the 
particular virtual screening workflow. Inactive test compounds are assigned a binary 
score value of zero (compound not captured) or one (compound captured) regardless to 
their individual fit values.79,81 
4. Overall True Positive Rate (TPR or overall sensitivity): describes the fraction percentage 
of captured actives from the total number of actives. Active test compounds are 
assigned a binary score value of zero (compound not captured) or one (compound 
captured) regardless to their individual fit values.79,81 
5. Overall False Negative Rate (FNR or overall percentage of discarded actives): 
describes the fraction percentage of active compounds discarded by the virtual 
screening method. Discarded active test compounds are assigned a binary score value 
of zero (compound not captured) or one (compound captured) regardless to their 
individual fit values.79,81 
2.5 In Silico screening  
Eventually, optimal QSAR-selected pharmacophores are employed as 3D search queries 
against several electronic multiconformer structural databases (e.g. NCI 238,819 structures) 
using the "Best Flexible Database Search" option implemented within CATALYST. 
Compounds that have their chemical groups spatially overlap (map) with corresponding 
features of the particular pharmacophoric model are captured as hits. Hits are normally 
filtered based on Lipinski's and Veber's rules.82,83 Surviving hits are then fitted against 
QSAR-selected pharmacophores and their fit values, together with other relevant molecular 
descriptors, are substituted in optimal QSAR equation to predict their bioactivities. The 
highest-ranking available hits are evaluated in vitro.  
Usually, the acquired hits are screened at 10 M concentrations, subsequently; compounds 
of significant bioactivities at 10 M are further assessed to determine their IC50 values.  
It remains to be mentioned that although QSAR predictions are rather accurate with some 
hit compounds, experimental IC50 values of other hits differ significantly from QSAR 
predictions. These errors appear are usually related to structural differences between 
training compounds used in QSAR and pharmacophore modeling compared to hit 
molecules. This discrepancy seems to limit the extrapolatory potential of the QSAR 
equation.  
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3. Conclusions 
This chapter summarizes an interesting novel approach for the discovery of new bioactive 
leads by implementing a sequential process of pharmacophore modeling and QSAR 
analysis. This approach has been used for the discovery of potent inhibitors against at least a 
dozen enzymes and receptors.  
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